Benitec Biopharma released its first quarter 2026 financial results and provided an operational update.
The company achieved positive interim clinical study results for BB-301 with a 100% responder rate in Cohort 1.
BB-301 was granted Fast Track Designation by the FDA for the treatment of Oculopharyngeal Muscular Dystrophy.
Benitec raised approximately $100 million in an oversubscribed public offering to advance the BB-301 program.
Fast Track Designation for BB-301
BB-301 received Fast Track Designation from the FDA based on positive interim clinical study results.
Capital Raise Success
Benitec raised approximately $100 million in a public offering to fund the advancement of BB-301.
Operational Milestones
BB-301 achieved a 100% responder rate in Cohort 1 and treated the first patient in Cohort 2 successfully.
- BB-301 has shown promising results in the treatment of Oculopharyngeal Muscular Dystrophy, with significant improvements in swallowing function.
- The Fast Track Designation by the FDA indicates the potential for accelerated development and regulatory review of BB-301.
Benitec Biopharma's success in the first quarter of 2026 highlights the positive outcomes of the BB-301 program and the company's commitment to advancing treatments for Oculopharyngeal Muscular Dystrophy.